Abstract
Tuberculosis remains a major infectious disease to humans. It accounts for approximately 8-9 million new cases worldwide and an estimated 1.6 million deaths annually. Effective treatments for tuberculosis consist of a combination of several drugs administered over long periods of time. Since Mycobacterium tuberculosis often acquires multiple drug resistant mechanisms, development of new drugs with innovative actions is urgently required. The 2C-methyl-D-erythritol 4-phosphate (MEP) pathway, in charge of the essential biosynthesis of isoprenoids, represents a promising and selective target for developing new drugs against tuberculosis. To date, only fosmidomycin, a molecule that targets the second enzyme of the MEP pathway, has reached clinical trials but recent advances elucidating the structure and kinetics of the MEP enzymes are likely to change this scenario. This review describes the structure, mechanism of action and inhibitors of the seven enzymes of the MEP pathway, with special attention to the reported studies in M. tuberculosis.
Keywords: Drug development, Fosmidomycin, Isoprenoid biosynthesis, MEP pathway, Mycobacterium tuberculosis, enzymes, homologous proteins, isomer, N-terminal
Current Medicinal Chemistry
Title: The Methylerythritol Phosphate (MEP) Pathway for Isoprenoid Biosynthesis as a Target for the Development of New Drugs Against Tuberculosis
Volume: 18 Issue: 9
Author(s): C. Obiol-Pardo, J. Rubio-Martinez and S. Imperial
Affiliation:
Keywords: Drug development, Fosmidomycin, Isoprenoid biosynthesis, MEP pathway, Mycobacterium tuberculosis, enzymes, homologous proteins, isomer, N-terminal
Abstract: Tuberculosis remains a major infectious disease to humans. It accounts for approximately 8-9 million new cases worldwide and an estimated 1.6 million deaths annually. Effective treatments for tuberculosis consist of a combination of several drugs administered over long periods of time. Since Mycobacterium tuberculosis often acquires multiple drug resistant mechanisms, development of new drugs with innovative actions is urgently required. The 2C-methyl-D-erythritol 4-phosphate (MEP) pathway, in charge of the essential biosynthesis of isoprenoids, represents a promising and selective target for developing new drugs against tuberculosis. To date, only fosmidomycin, a molecule that targets the second enzyme of the MEP pathway, has reached clinical trials but recent advances elucidating the structure and kinetics of the MEP enzymes are likely to change this scenario. This review describes the structure, mechanism of action and inhibitors of the seven enzymes of the MEP pathway, with special attention to the reported studies in M. tuberculosis.
Export Options
About this article
Cite this article as:
Obiol-Pardo C., Rubio-Martinez J. and Imperial S., The Methylerythritol Phosphate (MEP) Pathway for Isoprenoid Biosynthesis as a Target for the Development of New Drugs Against Tuberculosis, Current Medicinal Chemistry 2011; 18 (9) . https://dx.doi.org/10.2174/092986711795029582
DOI https://dx.doi.org/10.2174/092986711795029582 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Infective Protective Properties of S100 Calgranulins
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Flow and Microwave Assisted Synthesis of Medicinally Relevant Indoles
Current Green Chemistry Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Anti-TNF and Crohns Disease: When Should We Stop?
Current Drug Targets New Preparative Approaches for Micro and Nano Drug Delivery Carriers
Current Drug Delivery Current Management of Alcoholic Liver Disease
Current Drug Abuse Reviews Further Perspectives on Diabetes: NeuroRegulation of Blood Glucose
Neuroscience and Biomedical Engineering (Discontinued) Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Novel Drug Delivery Magnetite Nano-systems Used in Antimicrobial Therapy
Current Organic Chemistry Toll Like Receptor - Potential Drug Targets in Infectious Disease
Infectious Disorders - Drug Targets Rapid Nucleic Acid Reaction Circuits for Point-of-care Diagnosis of Diseases
Current Topics in Medicinal Chemistry Formulation and Evaluation of Isoniazid Loaded Nanosponges for Topical Delivery
Pharmaceutical Nanotechnology Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease
Current Topics in Medicinal Chemistry Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Editorial (Thematic Issue: Recent Updates on Biologically Active Heterocycles - Part 2)
Current Organic Chemistry